The new generation antimicrobial peptides

Our workContact us

 Latest news:

25th July 2023, A recently completed study in an in vivo ferret model shows very compelling results for LTX-109 compared to placebo in the treatment of Influenza virus infection.

About us

Pharma Holdings AS develops novel drugs for treatment of microbial infections.

Our new generation cationic peptidomimetic is the result of world-class research in the field of lytic peptides.

The lead compound LTX-109 is engineered based on a naturally occurring peptide which does not seem to trigger development of resistance, ensuring a sustainable way of fighting off infections [threatening the global health].

Effective first-line treatments against respiratory viral infections are still a huge unmet need. Pharma Holdings has developed a highly effective nasal spray to treat these infections. Our primary indication is Influenza in immunocompromised patients, with other indications to follow.


Broad spectrum and rapid action

The compound LTX-109 has a proven effect against a variety of bacteria, both gram positives and gram negatives, including multi-resistant bacteria such as MRSA. The effect is also proven in vitro and in vivo against a panel of respiratory viruses. It exerts its virucidal effect through disrupting the integrity of viral envelope, inducing lysis of the latter and immediate inactivation of the virus.

"We have shown that LTX-109 is very effective at eliminating bacterial biofilms formed by Pseudomonas aeruginosa, in this case killing it at only four times the concentration needed to kill planktonic, non-biofilm bacteria. This level of efficacy is quite unheard of with most other antibiotics."

– Prof. John Sigurd Svendsen


A privately owned Norwegian pharmaceutical company

Pharma Holdings AS is a privately owned pharmaceutical company with offices in Oslo and Tromsø, Norway. Our goal is to become one of the market leaders in the antimicrobial space. Originating from the well-known Scandinavian biotech “hub”, Pharma Holdings represent a compelling business case: Proprietary patented technology, acknowledged scientific experts, a highly competent management team, and a growing market demand for our solutions.

Sustainable antimicrobial combat

Our vision is to contribute in the constant battle against global infections in a eco-friendly way by developing new potent drugs based on the nature’s on defense mechanism.